

68th WEEKLY NEWSLETTER

USF INTERNAL MEDICINE & PEDIATRIC DIVISIONS OF ALLERGY AND IMMUNOLOGY

It is with much regret that we announce the resignation of Jennifer Leiding, MD, who has decided to pursue a position in the medical industry. Dr. Leiding has been an essential member of the Pediatric Division of Allergy and Immunology since completing her fellowship at NIH. She has served many roles, including the director of newborn screening for SCID, and is passionate about primary immunodeficiencies, both the clinical care of these patients and innovative research, and to develop new insights in this area. She has been an excellent mentor to many fellows. Her last day at USF will be August 13, 2021. We would like to thank Dr. Leiding for her great contributions to the Divisions of Allergy and Immunology and to medicine and wish her the best in her future endeavors.



Jennifer Leiding, MD with her husband, Dan Leiding, MD, and children, Alice and Freddy

From Jennifer Leiding, MD:

I was born and raised in St. Petersburg, FL, received my BS in Biology at USF, MD from USF in 2006, and did my pediatric residency at USF from 2006-2009. I then trained in Allergy/Immunology at NIAID and was a post-doctoral research fellow in the Laboratory of Clinical Infectious Diseases under Dr. Steven Holland.

I joined USF in 2012, rose to Associate Professor in 2017, and have served many roles which include Associate Director of the Center for Cell and Gene Therapy at Johns Hopkins-All Children's Hospital, Director of the Conjoint BMT-Immunology Clinic at JHACH, and Medical Director of SCID Newborn Screening. I am recognized nationally for my expertise in management of innate defects, specifically CGD; hematopoietic cell transplant of innate defects; and precision therapy for the treatment of inborn errors of immunity.

I am excited to remain a Lead Investigator within the Primary Immunodeficiency Treatment Consortium, Vice Chair of the Basic and Clinical Immunology Interest Section of the AAAAI, and Chair of the Diversity and Inclusion Committee of the CIS.

I will be joining Bluebird Bio as Medical Director within the Severe Genetic Diseases Section. Bluebird Bio is a well-know biotech company which develops gene therapy for hematologic conditions including sickle cell anemia, primary immunodeficiency diseases, and metabolic disorders. I will continue to reside with my family in St. Petersburg.

With warm regards,

Richard F. Lockey, MD
Distinguished University Health Professor
Joy McCann Culverhouse Chair in Allergy
and Immunology
Professor of Medicine, Pediatrics & Public Health
Director, Division of Allergy and Immunology
Department of Internal Medicine

Jolan Walter, MD, PhD
Robert A. Good Endowed Chair in Immunology
Associate Professor of Pediatrics and Medicine
Chief, Division of Allergy and Immunology
Department of Pediatrics